期刊
EPILEPSIA OPEN
卷 7, 期 1, 页码 11-26出版社
WILEY
DOI: 10.1002/epi4.12569
关键词
antiseizure medication; comorbidities; epilepsy; genetic diagnosis; treatment algorithm
Dravet syndrome is a severe and rare developmental and epileptic encephalopathy, impacting cognitive, psychomotor, and language abilities of patients, with drug-resistant epilepsy. Treatment of seizures may lead to better outcomes, and the updated guideline provides important information for healthcare professionals and families of DS patients.
Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic encephalopathy affecting 1 in 16 000 live births and characterized by a drug-resistant epilepsy, cognitive, psychomotor, and language impairment, and behavioral disorders. Evidence suggests that optimal treatment of seizures in DS may improve outcomes, even though neurodevelopmental impairments are the likely result of both the underlying genetic variant and the epilepsy. We present an updated guideline for DS diagnosis and treatment, taking into consideration care of the adult patient and nonpharmaceutical therapeutic options for this disease. This up-to-date guideline, which is based on an extensive review of the literature and culminates with a new treatment algorithm for DS, is a European consensus developed through a survey involving 29 European clinical experts in DS. This guideline will serve professionals in their clinical practice and, as a consequence, will benefit DS patients and their families.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据